Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Perrigo CoPRGO +4.56%53 3-Year EPS without NRI Growth Rate is 9.90% as of Jun. 2026, which is 29% above its 10-year median of 7.70. GuruFocus rates PRGO with a GF Score™ of 53/100 and a GF Value™ of $23.79 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 784 Drug Manufacturers companies, Perrigo Co ranks better than 50.26% on this metric.
During the past 12 months, Perrigo Co's average EPS without NRI Growth Rate was -15.10% per year.
During the past 3 years, the average EPS without NRI Growth Rate was 9.90% per year.
During the past 5 years, the average EPS without NRI Growth Rate was -2.90% per year.
During the past 10 years, the average EPS without NRI Growth Rate was -5.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Perrigo Co was 140.10% per year. The lowest was -58.20% per year. And the median was 7.70% per year.
Perrigo Co (NYSE:PRGO) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Perrigo Co 3-Year EPS without NRI Growth Rate Related Terms
PRGO vs ALVO, TRLV, ETON: 3-Year EPS without NRI Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Perrigo Co's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Perrigo Co 3-Year EPS without NRI Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Perrigo Co's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Perrigo Co's 3-Year EPS without NRI Growth Rate falls into.
Perrigo Co 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 9.90% mean?
Perrigo Co (PRGO) has a 3-Year EPS without NRI Growth Rate of 9.90% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Perrigo Co and its competitors. This is 29% above median its historical median of 7.70. According to the industry distribution chart, Perrigo Co ranks #390 out of 784 companies in the Drug Manufacturers industry, placing it in the top 49.7%.
Is Perrigo Co's 3-Year EPS without NRI Growth Rate too high?
Perrigo Co's current 3-Year EPS without NRI Growth Rate of 9.90% is 29% above median its 10-year median of 7.70. The Drug Manufacturers industry median 3-Year EPS without NRI Growth Rate is 9.80. Perrigo Co's value of 9.90% is 1% above this industry median. Based on the distribution chart, Perrigo Co ranks #390 out of 784 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Perrigo Co has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Perrigo Co's 3-Year EPS without NRI Growth Rate compare to ALVO and TRLV?
According to the Drug Manufacturers industry distribution chart, Perrigo Co ranks #390 out of 784 companies for 3-Year EPS without NRI Growth Rate. This puts Perrigo Co in the upper half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 9.80. Perrigo Co's value of 9.90% is 1% above this benchmark. While the company's 10-year median is 7.70 vs. the industry median of 9.80, Perrigo Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Drug Manufacturers company?
The median 3-Year EPS without NRI Growth Rate among Drug Manufacturers companies is 9.80, based on 784 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Perrigo Co's current 3-Year EPS without NRI Growth Rate of 9.90% is 1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Perrigo Co and its competitors. For the Drug Manufacturers industry, the median 3-Year EPS without NRI Growth Rate is 9.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Perrigo Co's current 3-Year EPS without NRI Growth Rate is 9.90%, which is 29% above median its own 10-year median of 7.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Perrigo Co stock overvalued right now?
Based on GuruFocus' analysis, Perrigo Co (PRGO) is currently considered Possible Value Trap. The stock's GF Value™ is $23.79, compared to a current price of $14.92 — trading 37.3% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 9.90%, which is 29% above median its 10-year median of 7.70 and 1% above the Drug Manufacturers industry median of 9.80. Perrigo Co's overall GF Score™ is 53/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Perrigo Co (PRGO), the current 3-Year EPS without NRI Growth Rate is 9.90% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Perrigo Co (PRGO) Overvalued in 2026?
Based on GuruFocus' analysis, Perrigo Co stock appears to be undervalued.
The current stock price of $14.92 is trading 37.3% below its estimated GF Value™ of $23.79.
GuruFocus considers Perrigo Co to be Possible Value Trap.
Key valuation signals for PRGO:
3-Year EPS without NRI Growth Rate: 9.90% (29% above median its 10-year median of 7.70)
GF Value™: $23.79 vs. price of $14.92 (37.3% below fair value)
Industry Position: 1% above the Drug Manufacturers median (#390 of 784)
No single metric tells the full story. See the PRGO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo has divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two-thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.
53GF Score
Get the complete analysis for PRGO
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRGO has been successfully added to your 
